Non-vitamin K antagonist oral anticoagulants reduce all-cause mortality, major bleeding and intracerebral hemorrhage but higher risk of gastro-intestinal bleeding according to a recent study including 18638 patients treated with DOACs versus 49418 on warfarin in Sweden.